At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...

Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

The FDA has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to ...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML ...